BCI
BCAX

Brinker Capital Investments’s Bicara Therapeutics BCAX Stock Holding History

Brinker Capital Investments’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,278
Closed -$190K – 2306
2025
Q4 		$190K Sell
11,278
-25
-0.2% -$427 ﹤0.01% 2035
2025
Q3 		$178K Buy
+11,303
New +$127K ﹤0.01% 1984

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Brinker Capital Investments's BCAX Position: Q1 2026 in Review

Brinker Capital Investments sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 11,278 shares — an estimated $190K sold.

Brinker Capital Investments first reported a position in BCAX in Q3 2025 and held it in 2 quarters. The position peaked at $190K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Brinker Capital Investments reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brinker Capital Investments sold 11,278 Bicara Therapeutics shares in Q1 2026, an estimated $190K.
  • Brinker Capital Investments first reported a position in Bicara Therapeutics in Q3 2025 and held it in 2 quarters.
  • Brinker Capital Investments's Bicara Therapeutics position peaked at $190K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.